Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-22
2011-03-22
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013300, C424S094500, C435S069700
Reexamination Certificate
active
07910554
ABSTRACT:
The Rho family of GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin fromClostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. These new antagonists are a significant improvement over C3 compounds because they are 3-4 orders of magnitude more potent to stimulate axon growth on inhibitory substrates than recombinant C3. The invention further provides methods of treating a disease of the eye by administering the compounds of the invention.
REFERENCES:
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5945290 (1999-08-01), Cowsert
patent: 6855688 (2005-02-01), McKerracher
patent: 7442686 (2008-10-01), Lasko et al.
patent: 2002/0032148 (2002-03-01), Uehata et al.
patent: 2002/0077283 (2002-06-01), Sessa
patent: 2003/0103957 (2003-06-01), McKerracher et al.
patent: 2005/0059595 (2005-03-01), Lasko et al.
patent: 2007/0270340 (2007-11-01), McKerracher et al.
patent: 2008/0269120 (2008-10-01), McKerracher et al.
patent: 2300878 (1999-02-01), None
patent: 2304981 (1999-05-01), None
patent: 2301157 (1999-11-01), None
patent: 2342970 AA (2002-10-01), None
patent: 585168 (1994-03-01), None
patent: 1177796 (2002-06-01), None
patent: WO 97/23236 (1997-07-01), None
patent: WO 99/23113 (1999-05-01), None
patent: 2005030248 (2005-04-01), None
patent: WO 2005/030248 (2005-04-01), None
patent: 2008022182 (2008-02-01), None
Wilde et al., Toxicon, 2001, vol. 39(11):1647-1660.
Borras, Exp. Eye Res., 2003, vol. 76, pp. 643-652.
Kimura et al., Adv. Drug Deliv. Rev., 2001, vol. 52(1):79-91.
ISR, Jul. 3, 2008.
ISR, Mar. 21, 2003.
Adler et al., Cell death in age-related macular degeneration, Molecular Vision, 1999: 5:31, pp. 31-36.
Curcio et al., Photoreceptor loss in age-related macular degeneration, Invest Ophthalmol Vis Sci, Jun. 1996;37 (7):1236-49 (Abstract only).
Fan et al., Differential regulation of A beta42-induced neuronal Clq synthesis and microglial activation,J. Neuroinflammation, 2005, 2:1, pp. 1-13.
Hahn et al., Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and . . . , PNAS, 2004, 101:38, pp. 13850-13855.
Klaver et al., Genetic Association of Apolipoprotein E with Age-Related Macular Degeneration, Am. J. Hum Genet.. 1998, 63:200-206.
Medeiros et al., Preservation of Ganglion Cell Layer Neurons in Age-related Macular Degeneration, Investigative Ophthalmology & Visual Science, 2001, 42:3, pp. 795-803.
Vander et al., Growth rate of subretinal newvascularization in age-related macumar degeneration, Ophthalmology, 1989, 96(9), pp. 1422-1426. (Abstract only).
E.I. Pecheur et al., Peptides and Membrane Fusion: Towards an Understanding of the Molecular Mechanism of Protein-Induced Fusion, J. Membrane Biol., 1999, 167:1-17, Springer-Verlag New York Inc.
Kazmierczak et al., Rho GTPase activity modulates Pseudomonas aeruginosa internalization by epithelial cells, Cellular Microbiology, 2001, 3:2, pp. 85-98.
Sauzeau et al., Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase, Circulation Research, 2001, 88:11, pp. 1102-1104.
Winton et al., A novel group of permeable Rho antagonists that promote axon regeneration on growth inhibitory substances. Society for Neuroscience Abstracts, 2001, 27:2, p. 2120. (Abstract only).
Lehmann et al., Inactivation of Rho signaling pathway promotes CNS axon regeneration, Journal of Neuroscience, 1999, 19:17, pp. 7537-7547.
Folkman et al., J. Biol. Chem. (1992), pp. 10931-10934, vol. 267.
Rojas et al., Nature Biotechnology (1998), pp. 370-375, vol. 16.
Vives et al., The Journal of Biological Chemistry (1997), pp. 16010-16017, vol. 272, No. 25.
Wender et al., Proc. Nat'l Acad. Sci, USA (2000), pp. 13003-13008, vol. 97, No. 24.
Derossi et al., The Journal of Biological Chemistry (1996), pp. 18188-18193, vol. 271, No. 30.
Wilde et al., The Journal of Biological Chemistry (2001), pp. 9537-9542, vol. 276, No. 12.
Aullo et al., The EMBO Journal (1993), pp. 921-931, vol. 12, No. 3.
Bloch-Gallego et al., The Journal of Cell Biological Chemistry (1993), pp. 485-492, vol. 120, No. 2.
Derossi et al., The Journal of Biological Chemistry (1994), pp. 10444-10450, vol. 269, No. 14.
Verschuren, H. et al., European Journal of Cell Biology (1997), pp. 182-187, vol. 73.
Imamura, F. et al., Jpn. J. Cancer Res. (2000), pp. 811-816, vol. 91.
Yoshioka, K. et al., FEBS Letters (1995), pp. 25-28, vol. 372.
Van Aelst, L. et al., Genes & Development (1997), pp. 2295-2322, vol. 11.
Wilde, C. et al., Journal of Biological Chemistry (2000), pp. 16478-16483, vol. 275, No. 22.
Aktories, K. et al., Trends in Cell Biology (1995), pp. 441-443, vol. 5.
Kemp , C.M. et al., Investigative Ophthalmology & Visual Science (1994), pp. 3154-3162, vol. 35. No. 8.
Dalke, C. et al., Experimental Eye Research (2005), pp. 503-512, vol. 81.
Winton, M.J. et al., Journal of Biological Chemistry (2002), pp. 32820-32829, Vo. 277.
Hirai, F. et al., Biochemical and Biophysical Research Communications (2007), vol. 356: 279-285.
Singh, A.T., et al., Endocrinology (2005), vol. 146(5): 2171-2175.
Majumder et al., J. Biol. Chem (1998), vol. 273(17), pp. 10099-10106.
Van Golen, et al., Neoplasia (2000), vol. 2(5), pp. 418-425.
Park, et al., Circ. Res. (2002), vol. 91(2), pp. 143-50.
Cleverly, et al., Oncogene (2000), vol. 19, pp. 13-20.
Moorman, et al., J. lmmunol. (1996). vol. 156(1), pp. 4146-4153.
Burger, J. Neuro-Oncology (1995), vol. 24, pp. 3-7.
Classification of Cancer—Grading, Staging, www.oncologychannel.com—published Sep. 1, 2002.
Fawell, et al., PNAS USA (1994), vol. 91, pp. 664-668.
Busca, et al., Mol. Biol. Chem. (1998), vol. 9, pp. 1367-1378.
Forget, et al., Clin. Exp. Metastasis (2002), vol. 19(1), pp. 9-15.
Pecheur, E. I., et al., J. Membrane Biol. (1999), 167:1-17, Springer-Verlag New York Inc.
Adler, et al., Molecular Vision (1999), 5:31, pp. 31-36.
Curcio, et al., Invest. Ophthalmol. Vis. Sci. (1996), Jun.; 37(7): 1236-49 (Abstract only).
Fan, et al., J. Neuroinflammation (2005), 2:1, pp. 1-13.
Hahn, et al., PNAS (2004), 101:38, pp. 13850-13855.
Klaver, et al., AM. J. Hum. Genet. (1998), 63:200-206.
Medeiros, et al., Investigative Ophthalmology & Visual Science (2001), 42:3, pp. 795-803.
Vander, et al., Ophthalmology (1989), 96(9), pp. 1422-1426 (Abstract only).
Ciardella, et al., Ophthalmol. Clin. N. Am. 15 (2002), pp. 453-458.
Borras T. et al., Experimental Eye Research 76 (2003), pp. 643-652.
Wenzel A., et al., Progress in Retinal and Eye Research 24 (2005), pp. 275-306.
Bertrand J., et al., Neurobiology of Disease (2006), doi:10.1016/j.nbd.2006.08.008.
Bertrand J., et al., The Journal of Neuroscience (2005), 25(5), pp. 1113-1121.
Flannery J. G., et al., ILAR Journal (1999), vol. 40(2).
Bioaxone Therapeutique Inc.
Kemmerer Elizabeth C.
Ogilvy Renault LLP
Xie Xiaozhen
LandOfFree
Treatment of macular degeneration with ADP-ribosyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of macular degeneration with ADP-ribosyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of macular degeneration with ADP-ribosyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663175